Somatrogon

Phase 3Small molecule

Pfizer

Somatrogon is one of 8 small molecule programs targeting Growth Hormone Deficiency. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Growth Hormone DeficiencyActive, not recruiting

Small for Gestational AgeRecruiting

Growth Hormone DeficiencyPreclinical

Active, not recruiting

Small for Gestational AgePhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Growth Hormone Deficiency

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Approved

24 2

LUM-201

LLumos Pharma

Phase 3

5 3

Somatrogon

Pfizer

Phase 3

4 4

Somavert

PPharmacia and Upjohn

Preclinical

1 5

Growth Hormone-Releasing Hormone

MMassachusetts General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Small for Gestational Age

NCT07226089

Q3 2028

Recruiting

Dwarfism, Pituitary

NCT06587035

Clinical

Trials by Indication[1]

Growth1 trial

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

Completed· Pfizer logo

Pfizer·Phase 3·NCT03831880·87 enrolled

Small for gestational age1 trial

Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.

Recruiting·RRabin Medical Center·Phase 3·NCT07226089·254 enrolled

Drug1 trial

A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations

Completed·OOPKO Health, Inc.·Phase 1·NCT03810664·49 enrolled

Dwarfism, Pituitary1 trial

A Multicenter, Non-interventional Prospective Active Surveillance Study Among Participants Receiving Somatrogon Under Routine Clinical Care in India

Recruiting· Pfizer logo

Pfizer··NCT06587035·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Somatrogon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Somatrogon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Somatrogon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Somatrogon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Trials by Indication[1]

Growth1 trial

Small for gestational age1 trial

Drug1 trial

Dwarfism, Pituitary1 trial

References

Drug Info

Quick Facts

Related News